11 Best Performing Healthcare Stocks to Buy Now

Page 4 of 10

7. Ascentage Pharma Group Internat (NASDAQ:AAPG)

YTD Performance: 39.87%

Number of Hedge Fund Holders: N/A

Ascentage Pharma Group Internat (NASDAQ:AAPG) is a clinical-stage biotech company developing novel therapies for hepatitis B virus, age-related diseases, and cancers. On April 28, the company released results from five preclinical studies featuring five of its drug candidates.

The Chief Medical Officer of Ascentage Pharma, Dr. Yifan Zhai, said that encouraging data from their investigation assets sheds a positive light on its strong and innovative pipeline. The studies are anticipated to catalyze and complement Ascentage Pharma Group Internat ‘s (NASDAQ:AAPG) clinical development. The company has plans to actively advance the clinical development of these programs to expand its treatment options.

On April 21, the company announced that two of its proprietary novel drugs have been included in the 2025 Chinese Society of Clinical Oncology Guidelines. In a report issued on March 27, Brian Cheng from J.P. Morgan initiated coverage of Ascentage Pharma Group Internat (NASDAQ:AAPG) with a Buy rating and set a price target of $27.00.

Page 4 of 10